Merida Capital Holdings

Founder Mitch Baruchowitz leads the firm. Merida's public materials do not name an additional CIO, investment committee, or other senior investment partners. The firm's thesis and portfolio construction trace back to Baruchowitz's published perspectives on cannabis normalization and infrastructure investing. For allocators, this signals concentrated decision risk alongside deep sector specialization.

No. Merida explicitly targets the infrastructure and services layer — cultivation technologies, processing equipment, pharmaceutical constituents, and ancillary products — not plant-touching businesses. This structural choice limits direct exposure to the highest-regulatory-risk segments of the cannabis industry while capturing growth in the supply chain buildout. The firm's own materials describe this as investing in providers of essential products and services to cannabis businesses.

Merida focuses on companies that have already transitioned from start-up to revenue generation. The firm describes its role as accelerating proven operating models and supercharging commercial pipelines, rather than incubating pre-revenue ventures. This positions Merida in the expansion and growth-stage segment of the cannabis infrastructure market, where business models have shown product-market fit but need capital and operational guidance to scale.

Merida's deal flow plausibly derives from Baruchowitz's long-tenured network in the cannabis industry, though the firm does not publish a specific sourcing methodology. As a sector-dedicated fund with a narrow thesis, its proprietary advantage likely rests on domain expertise and relationships that generalist PE firms cannot replicate efficiently. No third-party data on Merida's exact sourcing funnel is publicly available.

Merida structures its deployments through both commingled funds and co-investment vehicles. The firm reports five distinct funds alongside co-investments. Allocators can likely access Merida's strategy through fund commitments, though the specific terms, minimums, and LP composition are not publicly disclosed.

Merida avoids plant-touching cannabis businesses: direct cultivation, retail dispensaries, and consumer-facing brands that handle the cannabis flower or derivative products. The firm also does not invest outside the cannabis and hemp ecosystem, maintaining a pure-play sector concentration that excludes traditional technology, healthcare, or industrial investments beyond the cannabis supply chain.

Merida actively uses co-investment vehicles as part of its structure, signaling willingness to partner alongside other investors. However, the firm's website does not detail its co-investment criteria, minimum participation sizes, or rights for LPs to co-invest. For allocators, direct inquiry would be necessary to understand co-investment access and alignment terms.